Mirion Technologies, Inc. (MIR) Stock

Mirion Technologies, Inc. (MIR) is a Technology stock trading at $15.23 (as of 2026-08-20), with a market capitalization of $4.19B and a trailing P/E of 1102.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Mirion Technologies, Inc. develops radiation detection, measurement, analysis, and monitoring products and services. It operates through Medical and Industrial segments, serving medical providers for radiation oncology, diagnostics, and radionuclide therapy, and supporting industrial users with radiation safety, personal detection, identification equipment, and related analysis tools.

Understand Mirion Technologies, Inc.: how it makes money

Mirion Technologies sells radiation detection, measurement, analysis, and monitoring products and services, earning revenue by supplying medical and industrial radiation solutions (including quality assurance and dosimetry offerings) as well as service revenue.

Profit is primarily linked to converting demand into product revenue while maintaining contribution from service revenue, with performance shown through orders activity and the mix of product versus service sales across its Medical and Industrial businesses.

Revenue by segment (latest quarter)
Medical	$0.1B
Industrial	$0.2B

Business quality (Mixed): The company shows meaningful gross margin, but current operating margin is tight, so investor focus typically stays on orders and whether product and service revenue can support profitability.

Valuation: At 186× earnings, MIR trades 210% above the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

Order flow remains substantial, with Orders Including Paragon and Certrec Acquisitions at 0.29B USD: Large Opportunity Orders Awarded are 0.14B USD, indicating significant commercial wins within the order mix.
Gross margin is solid at 46.2%: This suggests the product and service offerings can generate profitability before operating expenses.
Service Revenue is a reported revenue component at 0.06B USD: A meaningful service line can help diversify revenue away from purely product sales.

Bear case

Operating margin is low at 1.4%: This leaves less room for execution missteps or cost pressure to impact profitability.
Demand softness signals appear in the order metrics, with Order Rate Decline of 30.0%: This can translate into weaker future product deliveries and revenue growth.
Some business lines show declines, including Revenue Decline - Labs and Research Business of 19.0% and Industrial Segment Revenue Decrease of 2.0% (Organic Revenue Decline - Industrial Segment of -2.4%): These trends can pressure both growth and operating leverage.

Valuation — source: SEC EDGAR (first-party)
Price	$15.23
Market Cap	$4.19B
P/E Ratio	1102.8
EV / EBITDA	22.4
Price / Book	2.23
Price / Sales	4.17
FCF Yield	2.9%
DCF Value (model)	$0.71
DCF Upside vs Price	-95.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$925.40M
Net Margin	3.1%
Revenue Growth (YoY)	9.1%
EPS Growth (YoY)	-4.4%
FCF Growth (YoY)	35.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.73 (distress)
Piotroski F-Score	7/9 (strong)

Valuation vs Sector & Industry
Stock P/E	1102.8
Sector P/E (Technology)	33.9
Industry P/E (Measuring & Control Equipment)	51.8
vs Sector	3150.2%
vs Industry	2027.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($710.71M)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	Thomas D. Logan
Employees	2,800
Country	US
IPO Date	2020-08-20

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.